Skip to Content
Merck
  • Functional genomics and the development of pathogenesis-targeted therapies for Kaposi's sarcoma.

Functional genomics and the development of pathogenesis-targeted therapies for Kaposi's sarcoma.

Pharmacogenomics (2005-07-15)
Shane C McAllister, Klaus Früh, Ashlee V Moses
ABSTRACT

Kaposi's sarcoma (KS) is a multifocal angioproliferative disorder affecting the skin, mucosa and viscera of individuals infected with human herpesvirus-8 (HHV-8; also Kaposi's sarcoma-associated herpesvirus [KSHV]). KS is the most common neoplasm in AIDS patients; the clinical outcome of AIDS-KS is significantly improved by highly active antiretroviral therapy (HAART). However, in Africa, where the severest manifestations of KS occur, there is limited access to these and other effective but expensive drugs. Here we present a review of current efforts to identify novel therapeutic targets for the treatment of KS using functional genomics, with recommendations regarding the development of economically feasible treatments for use in Africa.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Mesoporphyrin IX dihydrochloride, synthetic, 95%